-
公开(公告)号：US10316073B2
公开(公告)日：2019-06-11
申请号：US14580771
申请日：2014-12-23
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
公开(公告)号：US11505585B2
公开(公告)日：2022-11-22
申请号：US15821104
申请日：2017-11-22
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
公开(公告)号：US20180179258A1
公开(公告)日：2018-06-28
申请号：US15821104
申请日：2017-11-22
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
CPC分类号： C07K14/4703 , A61K38/00 , A61K38/1709 , A61K45/06 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/94
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
公开(公告)号：US20220275035A1
公开(公告)日：2022-09-01
申请号：US17672346
申请日：2022-02-15
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
公开(公告)号：US20150218239A1
公开(公告)日：2015-08-06
申请号：US14580771
申请日：2014-12-23
发明人： Peter Ulrichts , Christophe Blanchetot , Torsten Dreier , Johannes de Haard , E. Sally Ward Ober , Nicolas G. H. Ongenae
CPC分类号： C07K14/4703 , A61K38/00 , A61K38/1709 , A61K45/06 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/94
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
摘要翻译： 提供了新的FcRn拮抗剂组合物，其包含与FcRn特异性结合的变体Fc区，其具有增加的亲和力并降低相对于天然Fc区的pH依赖性。 还提供了具有增强的CD16结合亲和力的FcRn拮抗剂。 还提供了使用这些FcRn拮抗剂组合物治疗抗体介导的病症（例如自身免疫性疾病）的方法，编码FcRn拮抗剂组合物的核酸，用于制备FcRn拮抗剂组合物的重组表达载体和宿主细胞，以及包含FcRn拮抗剂的药物组合物 组合物。
-
公开(公告)号：US20190194277A1
公开(公告)日：2019-06-27
申请号：US16213422
申请日：2018-12-07
申请人： argenx BVBA
CPC分类号： C07K14/4703 , A61K9/0019 , A61K38/00 , A61K45/06 , A61P37/00 , C07K16/00 , C07K2317/52 , C07K2317/526 , C07K2317/92 , C07K2317/94
摘要： Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.027 秒)
